Research

Uncovering Solutions

Amylin scientists drive a process of continuous discovery focused on novel peptide hormones and their therapeutic potential for millions of people coping with diabetes, obesity, and other metabolic diseases. Their discovery process is designed to identify previously unknown peptide hormones—molecular chains of amino acids that circulate through the bloodstream and play important metabolic roles—uncover their therapeutic potential, and optimize their performance as innovative new therapies.

Amylin's research organization challenges the boundaries and processes of traditional drug research by following paths designed by nature. While most of the pharmaceutical industry screens against already described molecular targets to find potential drug candidates, Amylin takes an integrated biological approach, leveraging the advantages inherent in peptide hormones, such as low toxicology risk and a strong track record of commercial success.

A key resource developed over time is a proprietary polypeptide hormone library that includes more than 1,000 potentially valuable biologics taken from nature. These have been synthesized to create a rich source of compounds for ongoing research into functionality, utility, and therapeutic value in addressing unmet medical needs. Amylin researchers believe this very significant corporate asset is unmatched in the biotech and pharmaceutical industries.